These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 10147118)

  • 1. HA-1A in gram-negative sepsis.
    Jennings M
    Pharmacoeconomics; 1992 Sep; 2(3):248-9. PubMed ID: 10147118
    [No Abstract]   [Full Text] [Related]  

  • 2. Is HA-1A cost-effective?
    Jennings M
    Pharmacoeconomics; 1993 Jan; 3(1):84-6. PubMed ID: 10147125
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
    Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
    N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody.
    Kett DH; Quartin AA; Sprung CL; Fisher CJ; Peña MA; Heard SO; Zimmerman JL; Albertson TE; Panacek EA; Eidelman LA
    Crit Care Med; 1994 Aug; 22(8):1227-34. PubMed ID: 8045141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients.
    Chalfin DB; Holbein ME; Fein AM; Carlon GC
    JAMA; 1993 Jan; 269(2):249-54. PubMed ID: 8417245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of clinical study design on cost-effectiveness projections for the treatment of gram-negative sepsis with human anti-endotoxin antibody.
    Linden PK; Angus DC; Chelluri L; Branch RA
    J Crit Care; 1995 Dec; 10(4):154-64. PubMed ID: 8924965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A cost-effectiveness analysis of treatment with antiendotoxin monoclonal antibodies in gram-negative sepsis].
    Tebas P
    Med Clin (Barc); 1993 Dec; 101(19):757-8. PubMed ID: 8289526
    [No Abstract]   [Full Text] [Related]  

  • 8. Projected impact of monoclonal anti-endotoxin antibody therapy.
    Bates DW; Lee TH
    Arch Intern Med; 1994 Jun; 154(11):1241-9. PubMed ID: 8203991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis. Economic assessment of a new therapeutic agent.
    Schulman KA; Glick HA; Rubin H; Eisenberg JM
    JAMA; 1991 Dec; 266(24):3466-71. PubMed ID: 1744962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of HA-1A treatment for patients with sepsis.
    van Hout BA; Birnie E; Redekop WK; Lorijn RH; Bossuyt PM; Rutten FF
    Prog Clin Biol Res; 1994; 388():435-43. PubMed ID: 7831376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
    Barriere SL; Guglielmo BJ
    Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction of new technology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin.
    Luce JM
    Crit Care Med; 1993 Aug; 21(8):1233-41. PubMed ID: 8339592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economic impact and cost-effectiveness of monoclonal antibody therapy for sepsis.
    Chalfin DB; Fein AM
    Clin Infect Dis; 1993 Nov; 17 Suppl 2():S520-4. PubMed ID: 8274619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HA-1A monoclonal antibody for gram-negative sepsis.
    N Engl J Med; 1991 Jul; 325(4):279-83. PubMed ID: 2057029
    [No Abstract]   [Full Text] [Related]  

  • 15. HA-1A. A human monoclonal antibody for the treatment of gram-negative sepsis.
    Smith CR; Straube RC; Ziegler EJ
    Infect Dis Clin North Am; 1992 Mar; 6(1):253-66. PubMed ID: 1578120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The economic impact of HA-1A (Centoxin) against endotoxin.
    Barriere SL
    Pharmacoeconomics; 1992 Nov; 2(5):408-13. PubMed ID: 10147053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibody HA-1A for gram-negative shock.
    Smith C; Wortel C; Dixon W; Ziegler E
    Lancet; 1991 Sep; 338(8768):695-6. PubMed ID: 1679495
    [No Abstract]   [Full Text] [Related]  

  • 18. Monoclonal antibodies to endotoxin in the management of sepsis.
    Fang KC
    West J Med; 1993 Apr; 158(4):393-9. PubMed ID: 8317126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost-effectiveness analysis of human monoclonal antibody HA-1A in patients with sepsis syndrome].
    Van Hout BA; Rutten FF; Lorijn RH
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):360-4. PubMed ID: 8437635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Preventive interruption of the administration of HA-1A monoclonal antibody against endotoxin].
    Torrabadella de Reynoso P; Trilla A; Salgado A; Ribas J
    Med Clin (Barc); 1993 Apr; 100(13):518. PubMed ID: 8479241
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.